Christine M. Klaskin served as Agenus's Vice President of Finance and was a named executive officer for 2025; she resigned effective December 31, 2025. A portion of her salary in both 2025 and 2024 ($29,822) was allocated for services provided to Agenus affiliate MiNK Therapeutics and is also reported in MiNK's compensation disclosures.
She also signed Agenus's SEC filings in her capacity as Vice President of Finance.